C53C9.2 Antibody

What is C53C9.2 and why is it significant in C. elegans research?

C53C9.2 is a protein encoded by the C53C9.2 gene in Caenorhabditis elegans with the UniProt accession number Q09936. This protein has emerged as an important research target for understanding nematode biology, particularly in developmental and cellular processes. C53C9.2 antibodies are valuable tools for detecting and studying this protein's expression, localization, and function within the model organism. The significance of C53C9.2 lies in its potential role in fundamental biological processes that may have evolutionary conservation, making it relevant for comparative studies across species and potentially offering insights into broader biological mechanisms beyond nematode biology .

What are the key specifications of commercially available C53C9.2 antibodies?

Commercially available C53C9.2 antibodies typically feature the following specifications:

These antibodies are specifically designed to recognize the C53C9.2 protein in C. elegans samples with high specificity and sensitivity, making them suitable for various research applications .

How should C53C9.2 antibodies be stored and handled to maintain optimal activity?

For optimal preservation of C53C9.2 antibody activity, researchers should adhere to the following storage and handling guidelines:

• Store the antibody at -20°C or preferably -80°C for long-term storage

• Avoid repeated freeze-thaw cycles by aliquoting the antibody upon receipt

• When preparing working aliquots, use sterile techniques and maintain cold chain protocols

• Prior to use, thaw aliquots gradually on ice rather than at room temperature

• Centrifuge briefly before opening vials to collect any solution that may have gathered in the cap

• For working solutions, dilute in appropriate buffers immediately before use

• Document storage conditions, freeze-thaw cycles, and usage dates to monitor antibody performance

Improper storage can lead to protein denaturation, aggregation, and loss of epitope recognition capabilities. Researchers should routinely validate antibody performance through positive controls, especially when using older aliquots or after any deviation from recommended storage conditions .

What are the validated applications for C53C9.2 antibody in C. elegans research?

C53C9.2 antibody has been validated for several experimental applications in C. elegans research:

For each application, researchers should perform optimization experiments to determine the optimal antibody concentration, incubation conditions, and detection methods for their specific experimental setup. Validation using appropriate controls, including C53C9.2 mutant strains or knockdown samples, is essential for confirming antibody specificity .

How can I optimize Western blot protocols for C53C9.2 antibody detection?

Optimizing Western blot protocols for C53C9.2 detection requires attention to several critical parameters:

• Sample Preparation:

  • Use fresh C. elegans samples when possible

  • Include protease inhibitor cocktails during lysis

  • Maintain samples at 4°C throughout processing

  • Denature samples at 95°C for 5 minutes in reducing sample buffer

• Gel Electrophoresis:

  • Use 10-12% SDS-PAGE gels for optimal resolution

  • Load appropriate protein amount (typically 20-50 μg total protein)

  • Include molecular weight markers spanning 25-75 kDa range

• Transfer Conditions:

  • Use PVDF membranes (0.45 μm pore size) for optimal protein binding

  • Transfer at 100V for 1 hour or 30V overnight at 4°C

  • Verify transfer efficiency with reversible protein staining

• Blocking and Antibody Incubation:

  • Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

  • Incubate with primary antibody (1:1000-1:5000) overnight at 4°C

  • Wash thoroughly (3-5 times, 5-10 minutes each) with TBST

  • Incubate with HRP-conjugated secondary antibody (1:5000-1:10000) for 1 hour at room temperature

• Detection and Analysis:

  • Use enhanced chemiluminescence reagents for detection

  • Optimize exposure times to prevent signal saturation

  • Include positive and negative controls in each experiment

For troubleshooting, a systematic approach testing each variable independently is recommended, with particular attention to antibody concentration, incubation time, and washing stringency .

How can I validate the specificity of C53C9.2 antibody in my experimental system?

Validating antibody specificity is crucial for generating reliable data. For C53C9.2 antibody, researchers should implement multiple validation strategies:

• Genetic Validation:

  • Compare antibody signal between wild-type and C53C9.2 mutant or RNAi-treated worms

  • Use CRISPR/Cas9 knockout strains as negative controls

  • Employ epitope-tagged C53C9.2 strains as positive controls

• Immunological Validation:

  • Perform peptide competition assays with the immunizing antigen

  • Test antibody against recombinant C53C9.2 protein

  • Compare results from multiple antibodies recognizing different epitopes

• Technical Validation:

  • Confirm single band of expected molecular weight in Western blots

  • Verify subcellular localization consistency across different detection methods

  • Assess batch-to-batch variation when using different antibody lots

• Cross-Reactivity Assessment:

  • Test antibody against closely related C. elegans proteins

  • Verify absence of signal in heterologous expression systems lacking C53C9.2

Comprehensive validation should be documented and included in publications to ensure reproducibility and reliability of research findings. When inconsistencies are observed, researchers should consider factors such as post-translational modifications, protein complexes, or splice variants that might affect antibody recognition .

What are the considerations for using C53C9.2 antibody in co-immunoprecipitation studies?

Co-immunoprecipitation (Co-IP) with C53C9.2 antibody requires careful planning and optimization:

• Lysis Buffer Composition:

  • Use mild non-denaturing buffers to preserve protein-protein interactions

  • Test different detergent concentrations (0.1-1% NP-40, Triton X-100, or CHAPS)

  • Include protease and phosphatase inhibitors to prevent degradation

  • Consider using crosslinking agents for transient interactions

• Antibody Coupling:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Consider covalently coupling antibody to beads to prevent antibody contamination

  • Optimize antibody:bead:lysate ratios through preliminary experiments

• Experimental Controls:

  • Include isotype control antibodies to identify non-specific interactions

  • Perform reverse Co-IP when possible to confirm interactions

  • Include input, unbound, and wash fractions in analysis

• Washing Conditions:

  • Optimize stringency through buffer composition and wash number

  • Test salt concentration gradients (150-500 mM NaCl)

  • Consider including low concentrations of competitive detergents in later washes

• Analysis Considerations:

  • Use sensitive detection methods for low-abundance interacting proteins

  • Consider mass spectrometry for unbiased interactome analysis

  • Validate key interactions through orthogonal methods (proximity ligation, FRET)

The interaction stability, protein abundance, and complex size will significantly influence protocol optimization. Researchers should document all optimization steps and verification methods when reporting Co-IP results .

What factors may contribute to weak or absent signal when using C53C9.2 antibody?

When experiencing weak or absent signals with C53C9.2 antibody, consider these potential factors and solutions:

A systematic troubleshooting approach involves changing one variable at a time while keeping others constant. Document all optimization experiments to establish a reliable protocol for future studies .

How can I minimize background and non-specific binding when using C53C9.2 antibody?

Reducing background and non-specific binding is crucial for generating clear, interpretable results:

• Blocking Optimization:

  • Test different blocking agents (BSA, non-fat milk, normal serum, commercial blockers)

  • Extend blocking time to 2-3 hours at room temperature or overnight at 4°C

  • Include blocking agent in antibody dilution buffers

• Antibody Dilution and Quality:

  • Use higher dilutions of primary antibody (start with manufacturer recommendations)

  • Pre-absorb antibody with irrelevant proteins or tissue lysates

  • Filter antibody solutions through 0.22 μm filters to remove aggregates

• Washing Procedures:

  • Increase number and duration of washes (minimum 4-5 washes, 5-10 minutes each)

  • Use higher detergent concentrations in wash buffers (0.1-0.3% Tween-20)

  • Consider adding low salt (50-150 mM NaCl) to reduce ionic interactions

• Sample Preparation:

  • Ensure complete lysis and removal of debris through centrifugation

  • Pre-clear samples with protein A/G beads before antibody incubation

  • Optimize fixation protocols for immunohistochemistry applications

• Detection System:

  • Use highly cross-absorbed secondary antibodies

  • Consider direct conjugation of primary antibody to eliminate secondary antibody

  • Optimize substrate incubation time to maximize signal-to-noise ratio

Systematic testing of these parameters will help establish optimal conditions for specific detection while minimizing background interference .

How should developmental expression patterns of C53C9.2 be analyzed and interpreted?

Analyzing developmental expression patterns of C53C9.2 requires attention to several methodological considerations:

• Experimental Design:

  • Collect synchronized C. elegans populations at well-defined developmental stages

  • Include multiple biological and technical replicates

  • Use appropriate controls (housekeeping proteins, stage-specific markers)

• Quantification Methods:

  • For Western blot: Use densitometry with normalization to loading controls

  • For immunofluorescence: Measure fluorescence intensity across defined anatomical regions

  • For quantitative analyses: Use appropriate statistical tests for temporal patterns

• Data Visualization:

  • Present normalized expression levels across developmental stages

  • Include statistical analyses of stage-to-stage differences

  • Consider heatmaps for tissue-specific expression patterns

• Interpretation Framework:

• Validation Approaches:

  • Confirm protein-level observations with mRNA expression data

  • Correlate expression with phenotypic consequences of gene knockdown

  • Compare with expression patterns of known interaction partners

When interpreting developmental expression patterns, consider that post-translational modifications may affect antibody recognition, potentially leading to apparent expression changes that actually reflect modification states rather than absolute protein levels .

What advanced imaging techniques can enhance C53C9.2 localization studies in C. elegans?

Advanced imaging techniques can provide deeper insights into C53C9.2 localization and dynamics:

• Super-Resolution Microscopy:

  • Structured Illumination Microscopy (SIM): Achieves 100-130 nm resolution

  • Stimulated Emission Depletion (STED): Reaches 30-80 nm resolution

  • Photoactivated Localization Microscopy (PALM)/Stochastic Optical Reconstruction Microscopy (STORM): Provides 10-30 nm resolution

  • Benefits: Resolves subcellular structures beyond diffraction limit, enables visualization of protein nanoclusters

• Live Imaging Approaches:

  • CRISPR/Cas9 endogenous tagging with fluorescent proteins

  • Photoconvertible fluorescent protein fusions for pulse-chase experiments

  • Fluorescence Recovery After Photobleaching (FRAP) for protein dynamics

  • Benefits: Captures real-time protein behavior, avoids fixation artifacts

• Multi-Dimensional Imaging:

  • Multicolor co-localization with organelle markers

  • 3D volumetric reconstruction using Z-stacks

  • Time-lapse imaging across developmental stages

  • Benefits: Contextualizes protein location within cellular architecture

• Correlative Light and Electron Microscopy (CLEM):

  • Combines fluorescence localization with ultrastructural context

  • Immunogold labeling for electron microscopy

  • Benefits: Nanometer-scale resolution of protein localization relative to membranes and organelles

• Proximity Labeling Approaches:

  • APEX2 or BioID fusion for proximity proteomics

  • Split-GFP complementation for visualizing protein-protein interactions

  • Benefits: Identifies spatial relationships and interaction partners in situ

How can C53C9.2 antibody studies be integrated with genetic approaches in C. elegans?

Integrating antibody-based studies with genetic approaches provides comprehensive insights into C53C9.2 function:

• Combined Analysis Strategies:

  • Correlate protein expression/localization with mutant phenotypes

  • Assess antibody staining patterns in genetic backgrounds with altered C53C9.2 regulation

  • Use antibodies to validate CRISPR-engineered modifications (tags, mutations)

• Rescue Experiments:

  • Confirm antibody specificity by restoring signal in genetic rescue lines

  • Analyze protein localization in structure-function studies with domain deletions

  • Validate transgenic overexpression by quantitative immunoblotting

• Genetic Interaction Studies:

  • Examine C53C9.2 expression/localization in backgrounds with interacting genes disrupted

  • Assess phosphorylation or other modifications in kinase/phosphatase mutants

  • Compare subcellular distribution in trafficking or organelle biogenesis mutants

• Multi-level Analysis Framework:

• Temporal Control Strategies:

  • Use heat-shock or drug-inducible systems with antibody analysis

  • Combine optogenetic manipulation with fixed-timepoint antibody analysis

  • Correlate developmental stage-specific genetic requirements with protein expression patterns

This integrated approach enables researchers to connect genotype with molecular phenotype, providing mechanistic insights into C53C9.2 function within specific cellular contexts and genetic pathways .

What mass spectrometry approaches can complement C53C9.2 antibody studies?

Mass spectrometry (MS) techniques provide powerful complementary data to antibody-based studies:

• Protein Identification and Validation:

  • Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) to confirm antibody specificity

  • Targeted Selected Reaction Monitoring (SRM) for absolute quantification

  • Parallel Reaction Monitoring (PRM) for increased sensitivity and specificity

• Post-Translational Modification (PTM) Analysis:

  • Phosphoproteomics to identify regulatory phosphorylation sites

  • Glycoproteomics to characterize glycosylation patterns

  • Ubiquitylation profiling to assess protein degradation pathways

  • Benefits: Identifies modifications that may affect antibody recognition or protein function

• Protein-Protein Interaction Studies:

  • Immunoprecipitation coupled with MS (IP-MS) to identify interaction partners

  • Cross-linking MS (XL-MS) to map interaction interfaces

  • Hydrogen-Deuterium Exchange MS (HDX-MS) to assess conformational changes

  • Benefits: Provides unbiased interactome data beyond candidate approaches

• Spatial Proteomics:

  • Proximity labeling (BioID, APEX) coupled with MS for subcellular proteomics

  • Laser capture microdissection with MS for tissue-specific analysis

  • Benefits: Contextualizes antibody localization data with comprehensive proteomic landscapes

• Integrated MS Workflows:

When designing integrated antibody-MS studies, researchers should consider sample preparation compatibility, appropriate controls, and statistical approaches for data integration. The combination provides both targeted (antibody) and unbiased (MS) perspectives on C53C9.2 biology .

What are the emerging technologies that may enhance C53C9.2 antibody research?

Several emerging technologies show promise for advancing C53C9.2 antibody-based research:

• Advanced Antibody Engineering:

  • Nanobodies and single-domain antibodies for improved penetration in C. elegans tissues

  • Intrabodies with subcellular targeting sequences for in vivo visualization

  • Bispecific antibodies for simultaneous detection of C53C9.2 and interaction partners

• Spatial Transcriptomics and Proteomics:

  • Integration of antibody-based protein localization with spatial transcriptomics

  • In situ sequencing with immunofluorescence for multi-omic single-cell analysis

  • Imaging Mass Cytometry for highly multiplexed protein detection

• Microfluidic and Organ-on-Chip Approaches:

  • Microfluidic worm handling for high-throughput antibody screening

  • Automated phenotyping with integrated immunostaining

  • Controlled environment studies with real-time antibody-based biosensors

• Computational and AI-Enhanced Analysis:

  • Machine learning for automated detection of subtle localization changes

  • Integrative multi-omic data analysis incorporating antibody-based measurements

  • Predictive modeling of protein-protein interactions validated by antibody studies

• Genome Engineering Innovations:

  • Prime editing for precise modification of C53C9.2 epitopes

  • Base editing for introducing specific mutations without double-strand breaks

  • Orthogonal CRISPR systems for multiplexed genetic manipulation combined with antibody validation

These emerging technologies will enable researchers to study C53C9.2 with unprecedented resolution, throughput, and contextual understanding, potentially uncovering new functions and regulatory mechanisms .

How should researchers approach contradictory findings between antibody-based and genetic studies of C53C9.2?

When faced with discrepancies between antibody-based and genetic approaches, researchers should implement a systematic resolution strategy:

• Technical Validation:

  • Verify antibody specificity through multiple controls

  • Confirm genetic modification efficacy at DNA, RNA, and protein levels

  • Test multiple antibody clones or epitopes when available

  • Validate genetic tools (CRISPR edits, RNAi) with sequencing and expression analysis

• Biological Interpretation Framework:

  • Consider post-transcriptional regulation (protein may persist despite mRNA reduction)

  • Evaluate post-translational modifications affecting antibody recognition

  • Assess potential compensatory mechanisms in genetic models

  • Investigate tissue-specific or temporal differences in knockout vs. knockdown approaches

• Resolution Approaches:

  • Employ orthogonal methods to triangulate findings

  • Conduct epistasis experiments to place contradictions in pathway context

  • Use acute vs. chronic disruption to distinguish direct vs. adaptive effects

  • Perform detailed time-course analyses to identify transient effects

• Decision Framework for Contradictory Data:

• Reporting Recommendations:

  • Transparently document contradictions in publications

  • Present multiple lines of evidence without overinterpreting

  • Discuss limitations of each approach

  • Propose testable hypotheses to resolve contradictions

By systematically addressing contradictions, researchers can develop more nuanced understanding of C53C9.2 biology and potentially uncover novel regulatory mechanisms that explain the observed discrepancies .

What are the key considerations for using C53C9.2 antibody in developmental stage-specific analyses?

Developmental stage-specific analysis with C53C9.2 antibody requires careful attention to technical details:

• Synchronization Approaches:

  • Egg preparation by hypochlorite treatment for precisely timed populations

  • Temperature-shift protocols for temperature-sensitive mutants

  • Developmental milestone marking (e.g., molting, vulval formation) for staging individual worms

• Sample Processing Considerations:

  • Optimize fixation protocols for each developmental stage (permeability changes during development)

  • Adjust lysis conditions for different biomass and cuticle thickness

  • Consider sample enrichment for stages with low C53C9.2 expression

• Quantitative Analysis Framework:

  • Normalize to stage-specific housekeeping proteins (some standards vary across development)

  • Use ratiometric approaches with internal controls

  • Develop stage-specific standard curves for absolute quantification

• Imaging Considerations:

  • Standardize imaging parameters across developmental stages

  • Account for size differences when comparing signal intensities

  • Use anatomical landmarks for consistent region-of-interest analysis

• Statistical Analysis:

  • Apply appropriate statistical tests for time-series data

  • Account for developmental variability in experimental design

  • Consider mixed-effects models for nested experimental designs

By implementing these technical considerations, researchers can reliably detect developmental dynamics of C53C9.2 expression and localization, providing insights into its stage-specific functions and regulation .

How can researchers effectively combine C53C9.2 antibody with RNAi approaches?

Combining antibody detection with RNAi provides powerful insights into C53C9.2 function:

• Experimental Design Strategies:

  • Include time-course analyses to capture protein depletion kinetics

  • Design controls targeting known stable and unstable proteins

  • Use tissue-specific RNAi systems with corresponding immunohistochemistry

• RNAi Validation Approaches:

  • Quantify knockdown efficiency by Western blot

  • Use antibody detection to identify tissues resistant to RNAi

  • Assess potential compensatory upregulation of related proteins

• Advanced Combined Protocols:

  • RNAi in reporter strains with antibody co-staining

  • Sequential RNAi of multiple genes with antibody-based phenotyping

  • Pulsed RNAi with recovery monitored by antibody detection

• Analysis Framework:

• Troubleshooting Strategies:

  • For discrepancies between mRNA and protein knockdown, assess protein stability

  • For incomplete knockdown, optimize RNAi conditions or use combination approaches

  • For unexpected upregulation, investigate feedback mechanisms with complementary transcriptomics

This integrated approach allows researchers to connect the functional consequences of C53C9.2 depletion with molecular and cellular phenotypes, providing mechanistic insights into its biological roles .